Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic

Psychiatric Quarterly

Volumn 79, Issue 2, 2008, Pages 133-137

  Bastiaens, Leo ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

ADHD; Atomoxetine; Quality of life; Stimulants

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT;

ADOLESCENT; ADULT; ANALYTIC METHOD; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; PSYCHOTHERAPY; QUALITY OF LIFE; SCORING SYSTEM;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; APPETITE DEPRESSANTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 44449099555     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-008-9070-6     Document Type: Article

References (12)

1. Klassen AF, Miller A, Fine S: Health related quality of life in children and adolescents who have a diagnosis of ADHD. Pediatrics 114:e541-e547, 2004
2. Escobar R, Soutullo CA, Hervas A: Worse quality of life for children with newly diagnosed attention deficit hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:e364-e369, 2005
3. Perwien AR, Faries DE, Kratochvil CJ, et al.: Improvement in health-related quality-of-life in children with ADHD: an analysis of placebo-controlled studies of atomoxetine. Journal of Developmental and Behavioral Pediatrics 25:264-271, 2004
4. Lopez FA, Chandler MC, Biederman J, et al.: Long-term Adderall XR treatment improves quality of life in ADHD children. Abstract presented at the 156th annual meeting of the American Psychiatric Association, 2003
5. Bastiaens L, Dello Stritto C: Quality of life of children and adolescents during psychiatric treatment in a community mental health setting. Psychiatry 2:32-35, 2005
6. Bastiaens L: Effectiveness and tolerability of atomoxetine in a real-world ADHD population. Psychiatry 4(12):44-48, 2007
7. Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al.: The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. European Psychiatry 12:232-241, 1997
8. Gadow KD, Sprafkin J: Adolescent Symptom Inventory-4. Stony Brook, NY, Checkmate Plus LTD, 1997
9. Bastiaens L, Dello Stritto C: Validity and reliability of the Health and Life Functioning Scale. Abstract presented at the 51st annual meeting of the American Academy of Child and Adolescent Psychiatry, 2004
10. Geller D, Donnelly C, Lopez F: Atomoxetine treatment for pediatric patients with attention deficit hyperactivity disorder and comorbid anxiety. Journal of the American Academy of Child and Adolescent Psychiatry 46(9):1119-1127, 2007
11. Prasad S, Harpin V, Poole L: A multicentre randomised open label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention deficit hyperactivity disorder. Current Medical Research and Opinion 23(2):379-394, 2007
12. Bastiaens L: Pediatric psychopharmacology in a capitated managed care system: how do patients fare? Journal of Child and Adolescent Psychopharmacology 8(2):115-124, 1998